You are here

  • Home
  • Archive
  • Volume 71, Issue Suppl 3
  • LB0003 Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 adacta trial

Citation Tools

Article menu
Download PDFPDF
Scientific Abstracts
Late Breaking Abstracts
Late Breaking Abstract Session
LB0003 Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 adacta trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Gabay C, Emery P, van Vollenhoven R, et al
LB0003 Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 adacta trial
Annals of the Rheumatic Diseases 2013;71:152.